Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Stephen S Whitehead"'
Autor:
Leslie Goo, Pavle S. Milutinovic, Christina R. DeMaso, Kimberly A. Dowd, Theodore C. Pierson, Laura A. VanBlargan, Stephen S. Whitehead, Anna P. Durbin
Publikováno v:
J Virol
Dengue virus cocirculates globally as four serotypes (DENV1 to -4) that vary up to 40% at the amino acid level. Viral strains within a serotype further cluster into multiple genotypes. Eliciting a protective tetravalent neutralizing antibody response
Autor:
Jesica Swanstrom, Daniel Emerling, Kristen K. Pierce, Usha K. Nivarthi, Sean A. Diehl, Beth D. Kirkpatrick, Aravinda M. de Silva, Stephen S. Whitehead, Anna P. Durbin, Huy A. Tu, Ralph S. Baric, Ngan Nguyen, Bhumi Patel, Matthew J. Delacruz
Publikováno v:
EBioMedicine. 41:465-478
Background Acute viral infections induce a rapid and transient increase in antibody-secreting plasmablasts. At convalescence, memory B cells (MBC) and long-lived plasma cells (LLPC) are responsible for long-term humoral immunity. Following an acute v
Autor:
Bhumi Patel, Stephen S. Whitehead, Boyd Yount, Anna P. Durbin, Douglas G. Widman, Aravinda M. de Silva, Usha K. Nivarthi, Jesica Swanstrom, Ralph S. Baric, Matthew J. Delacruz
Publikováno v:
The Journal of Infectious Diseases
National Institutes of Health monovalent dengue vaccines and natural primary dengue virus infections elicit serotype-specific neutralizing antibodies that recognize similar epitopes.
Background Dengue virus is an emerging mosquito-borne flavivir
Background Dengue virus is an emerging mosquito-borne flavivir
Autor:
Nancy R. Graham, Stephen S. Whitehead, Anna P. Durbin, Usha K. Nivarthi, Jonathan E. Boyson, Huy A. Tu, Kristen K. Pierce, Matthew J. Delacruz, Philip Eisenhauer, Jason Botten, Aravinda Desilva, Beth D. Kirkpatrick, Sean A. Diehl
Publikováno v:
Cell Reports Medicine
Summary The tetravalent live attenuated dengue vaccine candidate TV003 induces neutralizing antibodies against all four dengue virus serotypes (DENV1–DENV4) and protects against experimental challenge with DENV2 in humans. Here, we track vaccine vi
Autor:
Jennifer E. Munt, Aravinda M. de Silva, Stephen S. Whitehead, Anna P. Durbin, Ralph S. Baric, Usha K. Nivarthi, Matthew J. Delacruz, David R. Martinez, Boyd Yount
Publikováno v:
Cell Reports, Vol 33, Iss 1, Pp 108226-(2020)
Cell reports
Cell reports
SUMMARY Dengue virus (DENV) infects an estimated 390 million people each year worldwide. As tetravalent DENV vaccines have variable efficacy against DENV serotype 2 (DENV2), we evaluated the role of genetic diversity within the pre-membrane (prM) and
Autor:
Beth D. Kirkpatrick, Melissa Cook, Michele Sausser, Beulah P. Sabundayo, Liman Wang, Stephen S. Whitehead, Helen He, Anna P. Durbin, Donna Hyatt, Kristen K. Pierce, Jeffrey R. Sachs, Beth Ann Coller, Amy Falk Russell, Andrew W. Lee, Jason C. Martin, Palmtama L. Grier
Publikováno v:
Am J Trop Med Hyg
New dengue vaccines are needed to prevent this globally expanding vector-borne disease. The V180 vaccine candidate consists of four recombinant, soluble, dengue virus envelope glycoproteins and has been previously evaluated in two clinical trials for
Autor:
Alexandra M. Ortiz, Samuel J. Magaziner, Erik P. Karmele, Joseph C. Mudd, Jason M. Brenchley, Theodore C. Pierson, Stephen S. Whitehead, Shelly J. Robertson, Heather D. Hickman, Carol L. Vinton, Kimberly A. Dowd, Emerito Amaro-Carambot, Sonja M. Best, Carly E. Starke
Publikováno v:
mBio
mBio, Vol 10, Iss 6, p e02790-19 (2019)
mBio, Vol 10, Iss 6 (2019)
mBio, Vol 10, Iss 6, p e02790-19 (2019)
mBio, Vol 10, Iss 6 (2019)
Immunocompromised individuals often become symptomatic with infections which are normally fairly asymptomatic in healthy individuals. The particular mechanisms that underlie susceptibility to coinfections in human immunodeficiency virus (HIV)-infecte
Autor:
Kristen K. Pierce, Kari Opert, Ellen A. Fraser, Marya P. Carmolli, Palmtama L. Grier, Benjamin D. McElvany, Kanta Subbarao, Catherine J. Luke, Stephen S. Whitehead, Beth D. Kirkpatrick, Anna P. Durbin, Eli A. Sendra, Janece M. Lovchik, Catherine J. Larsson, Cecilia M. Tibery, Beulah P. Sabundayo, Mary Claire Walsh, Noreen A. Hynes, Adrienne P. Jarvis, Matthew Jo
Publikováno v:
Journal of Infectious Diseases. 214:832-835
UNLABELLED The ideal dengue vaccine will provide protection against all serotypes of dengue virus and will be economical and uncomplicated in its administration. To determine the ability of a single dose of the live attenuated tetravalent dengue vacc
Autor:
Henry K. Cheng, Beth D. Kirkpatrick, Stephen S. Whitehead, Anna P. Durbin, Fiona R. Strouts, Stephen J. Popper, Eva Harris, Magelda Montoya, Janet C. Lindow, Angel Balmaseda, David A. Relman
Background: Several promising live attenuated virus (LAV) dengue vaccines are in development, but information about innate immune responses and early correlates of protection are lacking. Methods: We characterized human genome-wide transcripts in who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b290b2cbe48afd3f1ae1163b1196e69
Autor:
Stephen J. Popper, Henry K. Cheng, Janet C. Lindow, Beth D. Kirkpatrick, Magelda Montoya, David A. Relman, Eva Harris, Angel Balmaseda, Stephen S. Whitehead, Anna P. Durbin, Fiona R. Strouts
Publikováno v:
The Journal of infectious diseases. 218(12)
BACKGROUND: Several promising live attenuated dengue vaccines are in development, but information about innate immune responses and early correlates of protection is lacking. METHODS: We characterized human genome-wide transcripts in whole blood from